Hepatosplenic candidiasis in the era of new antifungal drugs: A study in Paris 2000-2007

36Citations
Citations of this article
38Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

We report a retrospective study of 24 patients with haematological malignancy and hepatosplenic candidiasis. Clinical and biological features were similar to previous reports. No patient previously received antifungal prophylaxis. Liver or spleen histological examination revealed yeasts in 6/24 patients (25%) on direct examination but all cultures were negative. After a median duration of 7months, antifungal treatment was discontinued in 58% of the patients with no relapse. Eleven (46%) patients died during follow up. After multivariate analysis, independent factors associated with death were the duration of neutropenia (p0.022) and relapsing haematological malignancy (p0.015). © 2012 European Society of Clinical Microbiology and Infectious Diseases.

Cite

CITATION STYLE

APA

De Castro, N., Mazoyer, E., Porcher, R., Raffoux, E., Suarez, F., Ribaud, P., … Molina, J. M. (2012). Hepatosplenic candidiasis in the era of new antifungal drugs: A study in Paris 2000-2007. Clinical Microbiology and Infection, 18(6). https://doi.org/10.1111/j.1469-0691.2012.03819.x

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free